GPCRs: Researchers Disprove the Single Polypeptide Theory

For this article, Jim Kling interviewed Bryen A. Jordan, postdoctoral scientist in the lab of Edward Ziff at the New York University School of Medicine's department of biochemistry; Theresa Branchek, vice president of research at Synaptic Pharmaceutical Corp. (Paramus, NJ); and Christophe Gerald, vice president of target discovery and assessment at Synaptic Pharmaceutical. Data from the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average

Written byJim Kling
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

This well-known family of seven-transmembrane-domain cell surface receptors respond to many signals, including photons, biogenic amines, lipids, peptides, and proteases. The receptors have many functions, most of them related to homeostatic control of processes such as blood pressure, respiration, and appetite.1 Studied for nearly 30 years, researchers thought they had a decent idea of what GPCRs looked like. "GPCRs have historically been thought to be single polypeptides," says Theresa Branchek, vice president of research at Synaptic Pharmaceutical Corp. Paramus, NJ.

The work at Synaptic Pharmaceuticals grew out of the company's focus on GPCRs in general. The GABA receptors include three types, A, B, and C, and the company focused on GABAB, in part because it is the only one of the three that is a GPCR, and also because Synaptic says it believes that the GABAB receptor will allow them to indirectly modulate pathways, perhaps producing a more subtle and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies